Identification of heparin-binding EGF-Like growth factor (HB-EGF) as a Biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  David, Marion ^a,b   Sahay, Debashish ^c,d   Mege, Florence ^c,e   Descotes, Françoise ^f   Leblanc, Raphaël ^c,d   Ribeiro, Johnny ^c,d   Cleźardin, Philippe ^c,d   Peyruchaud, Olivier ^c,d  

^a INSERM   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c University of Lyon Claude Bernard   (France)

^d UNIVERSITÉ LYON 1   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; KI 16425; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR TYPE 1; UNCLASSIFIED DRUG; 3-(4-(4-((1-(2-CHLOROPHENYL)ETHOXY)CARBONYL AMINO)-3-METHYL-5-ISOXAZOLYL) BENZYLSULFANYL) PROPANOIC ACID; ISOXAZOLE DERIVATIVE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; MESSENGER RNA; PROPIONIC ACID DERIVATIVE; TUMOR MARKER;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL LINE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LPAR1 GENE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HUMANS; ISOXAZOLES; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROPIONATES; PROSTATIC NEOPLASMS; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901348457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097771     Document Type: Article

References (42)

1. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, et al. (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26: 5015-5022.
2. Fukushima N, Shano S, Moriyama R, Chun J (2007) Lysophosphatidic acid stimulates neuronal differentiation of cortical neuroblasts through the LPA1-G(i/o) pathway. Neurochem Int 50: 302-307.
3. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, et al. (2006) Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281: 25822-25830.
4. Gennero I, Laurencin-Dalicieux S, Conte-Auriol F, Briand-Mesange F, Laurencin D, et al. (2011) Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone 49: 395-403.
5. David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, et al. (2014) Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. J Biol Chem.
6. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, et al. (2005) LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435: 104-108.
7. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, et al. (2008) Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 9: 415-423.
8. Moolenaar WH (2000) Development of our current understanding of bioactive lysophospholipids. Ann N Y Acad Sci 905: 1-10.
9. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, et al. (2010) LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-186.
10. Mutoh T, Rivera R, Chun J (2012) Insights into the pharmacological relevance of lysophospholipid receptors. Br J Pharmacol 165: 829-844.
11. Noguchi K, Herr D, Mutoh T, Chun J (2009) Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 9: 15-23.
12. Choi KU, Yun JS, Lee IH, Heo SC, Shin SH, et al. (2010) Lysophosphatidic acid-induced expression of periostin in stromal cells: Prognoistic relevance of periostin expression in epithelial ovarian cancer. Int J Cancer.
13. An S, Bleu T, Hallmark OG, Goetzl EJ (1998) Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 273: 7906-7910.
14. Tager AM, Lacamera P, Shea BS, Campanella GS, Selman M, et al. (2008) The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14: 45-54.
15. Miyabe Y, Miyabe C, Iwai Y, Takayasu A, Fukuda S, et al. (2013) Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum 65: 2037-2047.
16. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, et al. (2004) Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 10: 712-718.
17. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, et al. (2009) Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15: 539-550.
18. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, et al. (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 103: 9643-9648.
19. David M, Ribeiro J, Descotes F, Serre CM, Barbier M, et al. (2012) Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol 40: 1133-1141.
20. Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, et al. (2012) Effect of Inhibition of the Lysophosphatidic Acid Receptor 1 on Metastasis and Metastatic Dormancy in Breast Cancer. J Natl Cancer Inst.
21. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, et al. (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64: 994-1005.
22. Heise CE, Santos WL, Schreihofer AM, Heasley BH, Mukhin YV, et al. (2001) Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol 60: 1173-1180.
23. Yu S, Murph MM, Lu Y, Liu S, Hall HS, et al. (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100: 1630-1642.
24. Fang X, Yu S, Bast RC, Liu S, Xu HJ, et al. (2004) Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279: 9653-9661.
25. Pradere JP, Klein J, Gres S, Guigne C, Neau E, et al. (2007) LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 18: 3110-3118.
26. Guo F, Carter DE, Leask A (2011) Mechanical tension increases CCN2/CTGF expression and proliferation in gingival fibroblasts via a TGFbeta-dependent mechanism. PLoS One 6: e19756.
27. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, et al. (2001) Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 16: 2027-2034.
28. Boucharaba A, Serre C-M, Gres S, Saulnier-Blache JS, Bordet J-C, et al. (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 114: 1714-1725.
29. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
30. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, et al. (2004) Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 279: 17634-17639.
31. Peyruchaud O, Serre C-M, NicAmhlaoibh R, Fournier P, Clezardin P (2003) Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity. J Biol Chem 278: 45826-45832.
32. Sakamoto S, Yokoyama M, Zhang X, Prakash K, Nagao K, et al. (2004) Increased Expression of CYR61, an Extracellular Matrix Signaling Protein, in Human Benign Prostatic Hyperplasia and Its Regulation by Lysophosphatidic Acid. Endocrinology 145: 2929-2940.
33. Wiedmaier N, Muller S, Koberle M, Manncke B, Krejci J, et al. (2008) Bacteria induce CTGF and CYR61 expression in epithelial cells in a lysophosphatidic acid receptor-dependent manner. Int J Med Microbiol 298: 231-243.
34. Xue J, Gan L, Li X, Li J, Qi G, et al. (2010) Effects of lysophosphatidic acid and its receptors LPA(1/3) on radiation pneumonitis. Oncol Rep 24: 1515-1520.
35. Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, et al. (2005) HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res 7: R1058-1079.
36. Coulouarn C, Factor VM, Thorgeirsson SS (2008) Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47: 2059-2067.
37. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A (2005) TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 16: 1987-2002.
38. Cabello-Verrugio C, Cordova G, Vial C, Zuniga LM, Brandan E (2011) Connective tissue growth factor induction by lysophosphatidic acid requires transactivation of transforming growth factor type beta receptors and the JNK pathway. Cell Signal 23: 449-457.
39. Umata T, Hirata M, Takahashi T, Ryu F, Shida S, et al. (2001) A dual signaling cascade that regulates the ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 276: 30475-30482.
40. Zhao Y, He D, Saatian B, Watkins T, Spannhake EW, et al. (2006) Regulation of Lysophosphatidic Acid-induced Epidermal Growth Factor Receptor Transactivation and Interleukin-8 Secretion in Human Bronchial Epithelial Cells by Protein Kinase C{delta}, Lyn Kinase, and Matrix Metalloproteinases. J Biol Chem 281: 19501-19511.
41. Dusaulcy R, Daviaud D, Pradere JP, Gres S, Valet P, et al. (2009) Altered food consumption in mice lacking lysophosphatidic acid receptor-1. J Physiol Biochem 65: 345-350.
42. Inoue M, Ma L, Aoki J, Chun J, Ueda H (2008) Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain 4: 6.